araag2/HINT huggingface dataset:
Clinical trial NCT01183858 (phase 3, status: completed)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: erlotinib [tarceva]
SMILES: COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Adult patients aged ≥18 years

          -  inoperable, locally advanced (stage IIIB/IV) with supraclavicular lymph node
             metastases or malignant pleural or pericardial effusion) or metastatic (stage IV)
             non-small cell lung cancer (NSCLC)

          -  Disease must be characterized according to Response Evaluation Criteria in Solid
             Tumors (RECIST) criteria

          -  Patients have received one prior platinum-based chemotherapy regimen for advanced
             NSCLC, but must have recovered from any treatment-related toxicity

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2

          -  Life expectancy ≥12 weeks

          -  Current cigarette smoker (having smoked >100 cigarettes in entire lifetime and
             currently smoking on average ≥1 cigarette per day), not intending to stop during the
             study

        Exclusion Criteria:

          -  Prior antibody or small molecule therapy against Epidermal growth factor receptor
             (EGFR)

          -  Radiotherapy within 28 days prior to enrollment

          -  Received more than one line of chemotherapy for locally advanced/metastatic NSCLC
             (first-line maintenance chemotherapy after first-line platinum-based chemotherapy is
             allowed)
Clinical trial NCT01618162 (phase 3, status: completed)
Conditions: diabetes, diabetes mellitus, type 2
ICD codes: E23.2, N25.1, P70.2, O24.92, Z83.3, Z86.32, E10.65, E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: insulin degludec/liraglutide, placebo
SMILES: CN(C)C(=N)NC(N)=N, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with type 2 diabetes mellitus

          -  HbA1c 7.0-9.0% (53-75 mmol/mol) (both inclusive)

          -  Subjects on stable daily dose of sulphonylurea (above or equal to half of the max
             approved dose according to local label) with or without metformin (above or equal to
             1500 mg or max tolerated dose) for at least 90 days prior to screening visit (Visit 1)

          -  Body Mass Index (BMI) below or equal to 40 kg/m^2

        Exclusion Criteria:

          -  Any use of oral anti-diabetic drugs (OADs) (other than SU in monotherapy or in
             combinationwith metformin) below or equal to 90 days prior to screening visit (Visit
             1)

          -  Use of any drug (other than SU in monotherapy or in combination with metformin), which
             in the Investigators opinion could interfere with the blood glucose level (e.g.
             systemic corticosteroids)

          -  Previous treatment with glucagon-like peptide-1 (GLP-1) receptor agonist (e.g.
             exenatide, liraglutide)

          -  Treatment with any insulin regimen (short term treatment due to intercurrent illness
             including gestational diabetes is allowed at the discretion of the Investigator)

          -  Screening calcitonin above or equal to 50 ng/l

          -  Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine
             neoplasia type 2 (MEN2)

          -  Cardiovascular disorders defined as: congestive heart failure (New York Heart
             Association (NYHA) class III-IV), diagnosis of unstable angina pectoris, cerebral
             stroke and/or myocardial infarction within the past 52 weeks prior to screening visit
             (Visit 1) and/or planned coronary,carotid or peripheral artery revascularisation
             procedures

          -  Proliferative retinopathy requiring acute treatment or maculopathy (macular oedema)
             according to the Investigator's opinion

          -  Subjects with a clinical significant, active (during the past 12 months) disease of
             the gastrointestinal, pulmonary, endocrinological (except for the Type 2 Diabetes
             Mellitus),neurological, genitourinary or haematological system that in the opinion of
             the Investigator,may confound the results of the trial or pose additional risk in
             administering trial product

          -  History of chronic pancreatitis or idiopathic acute pancreatitis
Clinical trial NCT00058201 (phase 3, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: fluorouracil, gemcitabine hydrochloride, leucovorin calcium
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed ductal adenocarcinoma of the pancreas OR

          -  Histologically confirmed diagnosis of 1 of the following types of cancer:

               -  Acinar cell carcinoma or cystadenocarcinoma of the pancreas

               -  Cancers of the periampullary region

               -  Cancers of the intrapancreatic part of the bile duct

               -  Periampullary cancers of uncertain origin

          -  Complete macroscopic resection (R0 or R1 resection)

               -  Histological examination of all resection margins required

          -  No stage IVB disease

          -  No evidence of malignant ascites

          -  No liver or peritoneal metastases

          -  No evidence of spread to other distant abdominal or extra-abdominal organs

          -  No pancreatic lymphoma

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  WHO 0-2

        Life expectancy

          -  More than 3 months

        Hematopoietic

          -  Not specified

        Hepatic

          -  Not specified

        Renal

          -  Not specified

        Other

          -  Not pregnant

          -  Able to participate in long-term follow-up

          -  No other prior or concurrent malignancy except curatively treated basal cell skin
             cancer or carcinoma in situ of the cervix

          -  No serious medical or psychological condition that would preclude study treatment

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  No neoadjuvant chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  Not specified

        Surgery

          -  See Disease Characteristics

          -  Recovered from prior resection
Clinical trial NCT01116206 (phase 3, status: completed)
Conditions: constipation
ICD codes: K59.00, K59.09, K59.01, K59.02, K59.03, K59.04, K58.1
Drugs: prucalopride, placebo
SMILES: COCCCN1CCC(CC1)NC(=O)C1=C2OCCC2=C(N)C(Cl)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  History of chronic constipation, defined as on average, 2 or fewer spontaneous bowel
             movements (SBMs) per week and 1 or more of the following for at least a quarter of the
             time for the last 3 months, while symptom onset was more than 6 months before the
             screening visit: in more than 25 percent (%) of BMs, participants had very hard
             (little balls) and/or hard stools, sensation of incomplete evacuation, straining at
             defecation (making a bowel movement), sensation of ano-rectal obstruction or blockade,
             and/or need for digital manipulation to facilitate evacuation

          -  Participants who were considered as constipated (who never had SBMs)

          -  Participant's constipation is functional

          -  Participants with the diagnosis of irritable bowel syndrome (bowel disorder in which
             there is pain and diarrhea or constipation) with constipation and with no other
             organic diseases can potentially be included depending on the decision of the
             investigator

          -  Female participants must be postmenopausal (for at least 1 year) or surgically sterile
             or practicing a highly effective method of birth control

        Exclusion Criteria:

          -  Secondary to other diseases/conditions (endocrine disorders, metabolic disorders or
             neurologic disorders or drug-induced or suspected organic disorders of the large
             bowel, i.e., obstruction, carcinoma (type of cancer), or inflammatory bowel disease)

          -  - Participants Using or intending to use disallowed medications that may influence the
             bowel habit during the study

          -  Participants with severe (very serious, life threatening) and clinically uncontrolled
             cardiovascular, liver, or lung disease, neurologic or psychiatric disorders (including
             active alcohol or drug abuse), cancer (abnormal tissue that grows and spreads in the
             body until it kills) or acquired immune deficiency syndrome (AIDS: illness that
             results in decreased ability of the body to protect itself from other illnesses;
             development of the disease or conditions associated with the disease results from
             Human Immunodeficiency Virus [HIV]), or other gastrointestinal or endocrine disorders

          -  Participants with impaired renal function, that is, serum creatinine greater than 2
             milligram per deciliter (greater than 180 micro mole per liter)

          -  Participants with clinically significant abnormalities of hematology, urinalysis, or
             blood chemistry
Clinical trial NCT01287260 (phase 3, status: completed)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: nifedipine (adalat, baya1040), nifedipine (adalat, baya1040)
SMILES: COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC, COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OC
Eligibility criteria:

        Inclusion Criteria:

          -  20 years or older

          -  Japanese male or female

          -  Outpatient with essential hypertension

          -  Patients whose sitting diastolic blood pressure (DBP) is 90 mmHg or more despite more
             than 4 weeks of treatment with antihypertensive drug

        Exclusion Criteria:

          -  Sitting diastolic blood pressure (DBP) is 110 mmHg or more or sitting systolic blood
             pressure (SBP) is 180 mmHg or more

          -  Patients with secondary hypertension or hypertensive emergency
Clinical trial NCT00362466 (phase 3, status: terminated)
Conditions: leukemia
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01
Drugs: dasatinib, imatinib
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1
Reason stopped: 
    insufficient enrollment
  
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women ≥18 years diagnosed with Chronic Phase Philadelphia chromosome positive
             (CP Ph+) CML who have failed to achieve CCyR after 3-18 months of therapy with
             imatinib 400 mg

          -  Treatment initiation with imatinib 400 mg within 6 months of initial CML diagnosis

          -  Able to tolerate chronic administration of imatinib at the highest dose (400-600 mg)
             the subject has received in the past

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2

          -  Adequate hepatic and renal function

        Exclusion Criteria:

          -  Eligible and willing to undergo immediate autologous/allogeneic stem cell transplant

          -  Previous diagnosis of accelerated/blast crisis CML

          -  Subjects with clonal evolution in Ph+ cells observed in ≥2 metaphases

          -  Previous documentation of T315I mutation

          -  Uncontrolled or significant cardiovascular disease

          -  Serious uncontrolled medical disorder/active infection

          -  History of significant bleeding disorder unrelated to CML

          -  Intolerance to imatinib ≥400 mg

          -  Concurrent malignancies other than CML
Clinical trial NCT00501345 (phase 3, status: terminated)
Conditions: thrombocytopenia, myocardial infarction
ICD codes: D69.6, D69.49, D69.59, P61.0, D75.82, D69.42, O36.8211, I25.2, I21.9, I21.A1, I21.A9, I21.4, I22.2, I23.8
Drugs: aspirin
SMILES: CC(=O)OC1=CC=CC=C1C(O)=O
Reason stopped: 
    low accrual, study terminated.
  
Eligibility criteria:

        Inclusion Criteria:

          1. Presenting for Cardiology consult at M.D. Anderson Cancer Center.

          2. Platelet count between 100,000 and 20,000.

          3. Acute Coronary Syndrome diagnosed with their first 12 lead EKG.

          4. Patients that continue to show evidence of MI by cardiac enzymes with CPK levels > 2
             normal limits, CK-MB levels 10% above normal limits, and Troponin I levels > 1.4ug/L
             will be considered positive for MI.

          5. Ability to give consent.

        Exclusion Criteria:

          1. Contraindications to aspirin including severe intolerance or true allergy, active
             bleeding, hemophilia, active retinal bleeding, severe untreated hypertension, active
             peptic ulcer, or other significant source of gastrointestinal or genitourinary
             bleeding, brain metastasis, and altered mental status.

          2. Unwillingness or inability to give consent.

          3. Progressive heart failure, unstable angina not responding to medical therapy for 24
             hours, or ventricular tachycardia, necessitating thrombolysis, and angioplasty.

          4. Patients that rule out for MI by cardiac enzymes panel after the first 24 hours.

          5. Patients that rule in for MI and have Platelet count > 100,000.

          6. Patients with platelet count < 20,000.
Clinical trial NCT01103323 (phase 3, status: completed)
Conditions: metastatic colorectal cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: regorafenib (stivarga, bay73-4506), placebo
SMILES: O=[Zn], CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological documentation of adenocarcinoma of the colon or rectum

          -  Progression during or within 3 months following the last administration of approved
             standard therapies. Patients treated with oxaliplatin in an adjuvant setting should
             have progressed during or within 6 months of completion of adjuvant therapy

          -  Patients with measurable or non measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of </= 1

          -  Life expectancy of at least 3 months

          -  Adequate bone marrow, liver and renal function

        Exclusion Criteria:

          -  Unstable/uncontrolled cardiac disease

          -  History of arterial or venous thrombotic or embolic events

          -  Symptomatic metastatic brain or meningeal tumors

          -  Patients with evidence or history of bleeding diathesis

          -  Interstitial lung disease - Persistent proteinuria >/= grade 3

          -  Unresolved toxicity > grade 1 attributed to any prior therapy/procedure excluding
             alopecia and oxaliplatin induced neurotoxicity </= Grade 2
Clinical trial NCT00379769 (phase 3, status: completed)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: rosiglitazone, sulfonylurea, metformin
SMILES: CCN1C=C(C(O)=O)C(=O)C2=C1C=C(C=C2)C1=CC=NC=C1, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with type II diabetes mellitus as defined by 1999 World Health Organisation
             criteria.

          -  Glycated haemoglobin (HbA1c) >7.0 % to = 9.0 % at visit 1.

          -  Use of an oral glucose lowering agent for a minimum of 6 months prior to screening and
             unchanged for 2 months prior to screening.

          -  Body mass index >25.0 kg/m2.

        Exclusion Criteria:

          -  Patients receiving any other glucose lowering therapy which is not metformin or a
             sulfonylurea.

          -  Patients with systolic blood pressure >180 mmHg or diastolic blood pressure >105 mmHg.

          -  Patients who have required the use of insulin for glycaemic control at any time in the
             past.

          -  Hospitalisation for any major cardiovascular event in the last 3 months.
Clinical trial NCT00518323 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone er, placebo, paliperidone er, paliperidone er
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1, CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Must meet the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM
             IV) criteria for schizophrenia (295.10, 295.20, 295.30, 295.60, 295.90) for 1 year
             (the diagnosis will be established using the K-SADS-PL, including all supplements)

          -  Must not be a danger to themselves or others, and must have family support available
             to be maintained as an outpatient

          -  Should have had at least 1 adequate treatment with an antipsychotic before
             participation in this study

          -  Must have a PANSS score between 60 and 120, inclusive, at screening and baseline

          -  Weight >=29 kg

        Exclusion Criteria:

          -  Meet the DSM-IV criteria at screening for dissociative disorder, bipolar disorder,
             major depressive disorder, schizoaffective disorder, schizophreniform disorder,
             autistic disorder, or primary substance induced psychotic disorder. Other comorbid
             disorders e.g., attention-deficit hyperactivity disorder (ADHD) are allowed as long as
             the diagnosis of schizophrenia is the primary diagnosis and the comorbid disorders in
             the investigator's judgment do not require medication

          -  Mild, moderate, or severe mental retardation (i.e., documented intelligence quotient
             [IQ] <70) established by previous IQ testing or history

          -  Women who are pregnant (as confirmed by urine pregnancy test performed at screening or
             baseline), planning to become pregnant or are nursing

          -  Have a known or suspected history of seizure disorder, or neuroleptic malignant
             syndrome, encephalopathic syndrome, tardive dyskinesia, or insulin dependent diabetes
             mellitus

          -  Presence of any significant or unstable cardiovascular, respiratory, renal, hepatic,
             hematologic, endocrine, immunologic, or other systemic disease
Clinical trial NCT00033735 (phase 3, status: completed)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: fluorouracil, irofulven
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, CC1=C(CO)C2=C(C)C3(CC3)[C@@](C)(O)C(=O)C2=C1
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically or cytologically confirmed ductal carcinoma of the
        exocrine pancreas Locally advanced or metastatic Failed 1, but no more than 1, prior
        gemcitabine-containing chemotherapy regimen (either as a single agent or in combination
        with another agent) (See criteria for prior radiation using gemcitabine or fluorouracil at
        diminished doses in Prior/Concurrent Therapy section) No neuroendocrine or islet cell
        tumors or lymphoma of the pancreas

        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Karnofsky 70-100% Life
        expectancy: Not specified Hematopoietic: WBC at least 3,000/mm3 Platelet count at least
        100,000/mm3 Hemoglobin at least 9 g/dL Absolute neutrophil count at least 1,500/mm3
        Hepatic: Bilirubin no greater than 2.0 mg/dL AST or ALT no greater than 5.0 times upper
        limit of normal (ULN) Alkaline phosphatase no greater than 5.0 times ULN Renal: Creatinine
        no greater than 1.5 mg/dL Cardiovascular: No clinically significant active heart disease
        Other: Fertile patients must use effective contraception No history of retinopathy or
        macular degeneration No other malignancy within the past 5 years except basal cell or
        squamous cell skin cancer or carcinoma in situ of the cervix No other significant medical
        and/or psychiatric condition that would preclude study

        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior biologic therapy No concurrent
        biologic therapy Chemotherapy: See Disease Characteristics At least 21 days since prior
        chemotherapy and recovered No prior systemic treatment with fluorouracil,
        fluorouracil-uracil, raltitrexed, or capecitabine in combination with gemcitabine Prior
        fluorouracil or gemcitabine allowed as radiosensitizing agents when given 2 weeks before,
        during, or 2 weeks after radiotherapy No prior cumulative mitomycin dose greater than 25
        mg/m2 Endocrine therapy: Not specified Radiotherapy: At least 21 days since prior
        radiotherapy and recovered Surgery: No prior surgery No concurrent surgery Other: At least
        21 days since prior participation in other investigational study
Clinical trial NCT00363142 (phase 3, status: completed)
Conditions: hiv infection, infection, human immunodeficiency virus
ICD codes: Z21, Z21
Drugs: half-boosted fosamprenavir, full boosted fosamprenavir
SMILES: CC(C)CN(C[C@@H](OP(O)(O)=O)[C@H](CC1=CC=CC=C1)NC(=O)O[C@H]1CCOC1)S(=O)(=O)C1=CC=C(N)C=C1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion criteria:

          -  Subjects with HIV-1 infection.

          -  Are willing and able to understand and provide written consent prior to participation
             in this study.

        Exclusion criteria:

          -  Are pregnant or breastfeeding.

          -  Have an active AIDS condition, pancreatitis, poor kidney function, or clinically
             relevant hepatitis.

          -  Have certain medical conditions that may make participation unsafe.

          -  Take medication that may interact with the study medication.

          -  Have a history of allergy to any of the study drugs or any excipients therein.

          -  Other inclusion/exclusion criteria to be evaluated by the physician.